Biostar Report issue

For profit Phase 2 Phase 3
Founded: Beijing China (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2007
NCT01302015
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing Biostar Technologies, Ltd | Biostar | Chengdu Biostar Pharmaceuticals, Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Thromboangiitis Obliterans (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5